Recce Pharmaceuticals (ASX:RCE) Presentation, FNN Investor Event, November 2018, Melbourne

Company Presentations

Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham provides an update on the company's RECCE 327 product for use in targeting antibiotic resistant bacteria and its clinical pathway at FNN's Investor Event.

Key points:

  • A drug discovery and development business
  • Commercialising a new class of synthetic antibiotics for resistant superbugs
  • Qualified Infectious Disease Product designation RECCE 327
  • Sepsis kills more people in the U.S. than prostate, breast and lung cancer
  • Sepsis is the number 1 most expensive condition
  • Currently no drug therapies specifically for the treatment of sepsis

For more, watch Executive Director, James Graham present. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.